Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients
详细信息 查看全文
- 作者：Lucy J Campbell (1)
Tracy Dew (2)
Rashim Salota (2)
Emily Cheserem (3)
Lisa Hamzah (1) (3)
Fowzia Ibrahim (1)
Pantelis A Sarafidis (1)
Caje F Moniz (2)
Bruce M Hendry (1)
Mary Poulton (3)
Roy A Sherwood (2)
Frank A Post (1) (3) - 关键词：Proteinuria ; Albuminuria ; Retinol ; binding protein ; RBP ; Cystatin C ; Neutrophil gelatinase ; associated lipocalin ; NGAL ; Tenofovir ; HIV
- 刊名：BMC Nephrology
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：13
- 期：1
- 全文大小：372KB
- 参考文献：1. Post FA, Holt SG: Recent developments in HIV and the kidney. / Curr Opin Infect Dis 2009,22(1):43-8. CrossRef
2. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD: Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. / AIDS 2004,18(3):541-46. CrossRef
3. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, Fields TA, Svetkey LP, Flanagan KH, Klotman PE, / et al.: The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. / Kidney Int 2004,66(3):1145-152. CrossRef
4. Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, Siwani R, Johnson L, Fisher M, Holt SG, Bhagani S, / et al.: Predictors of renal outcome in HIV-associated nephropathy. / Clin Infect Dis 2008,46(8):1282-289. CrossRef
5. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG: HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. / AIDS 2009,23(16):2143-149. CrossRef
6. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, / et al.: CD4+ count-guided interruption of antiretroviral treatment. / N Engl J Med 2006,355(22):2283-296. CrossRef
7. Reid A, Stohr W, Walker AS, Williams IG, Kityo C, Hughes P, Kambugu A, Gilks CF, Mugyenyi P, Munderi P, / et al.: Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. / Clin Infect Dis 2008,46(8):1271-281. CrossRef
8. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, Smurzynski M, Albert JM: Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. / AIDS 2008,22(4):481-87. CrossRef
9. Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG: HIV viremia and changes in kidney function. / AIDS 2009,23(9):1089-096. CrossRef
10. Ibrahim F, Naftalin C, Cheserem E, Roe J, Campbell LJ, Bansi L, Hendry BM, Sabin C, Post FA: Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. / AIDS 2010,24(14):2239-244. CrossRef
11. Atta MG, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ, Fine DM: Antiretroviral therapy in the treatment of HIV-associated nephropathy. / Nephrol Dial Transplant 2006,21(10):2809-813. CrossRef
12. Bansi L, Hughes A, Bhagani S, Mackie NE, Leen C, Levy J, Edwards S, Connolly J, Holt SG, Hendry BM, / et al.: Clinical epidemiology of HIV-associated end-stage renal failure in the UK. / AIDS 2009,23(18):2517-521. CrossRef
13. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, Beniowski M, Viard JP, Staszewski S, Lundgren JD: Chronic renal failure among HIV-1-infected patients. / AIDS 2007,21(9):1119-127. CrossRef
14. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. / AIDS 2010,24(11):1667-678. CrossRef
15. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA: Spectrum of chronic kidney disease in HIV-infected patients. / HIV Med 2009,10(6):329-36. CrossRef
16. / Prevention and management of non-infectious co-morbidities in HIV. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-6.pdf
17. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ, / et al.: Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. / Clin Infect Dis 2005,40(11):1559-585. CrossRef
18. Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti AM, Kelleher P, Mackie N, Muir D, / et al.: British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. / HIV Med 2012,13(1):1-4. CrossRef
19. Izzedine H, Deray G: The nephrologist in the HAART era. / AIDS 2007,21(4):409-21. CrossRef
20. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G: Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. / Clin Infect Dis 2006,42(2):283-90. CrossRef
21. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, Connolly JO: Tenofovir-associated renal and bone toxicity. / HIV Med 2009,10(8):482-87. CrossRef
22. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Ceron D: Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. / J Acquir Immune Defic Syndr 2004,35(3):269-73. CrossRef
23. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, Launay-Vacher V, Deray G: Renal safety of tenofovir in HIV treatment-experienced patients. / AIDS 2004,18(7):1074-076. CrossRef
24. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, Rivas P, Albalater M, Blanco F, Moreno V, / et al.: Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. / AIDS 2009,23(6):689-96. CrossRef
25. Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O'Farrell S, Unwin RJ, Williams IG: Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. / Am J Kidney Dis 2009,54(6):1034-042. CrossRef
26. Fux C, Opravil M, Cavassini M, Calmy A, Flepp M, Gurtner-Delafuente V, Stoeckle M, Schmid P, Rauch A, Furrer H, / et al.: 16th Conference on Retroviruses and Opportunistic Infections. In / Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study. Montreal, Canada; 2009.
27. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, Cuenca L, Gonzalez-Pardo G, Khoo S, Back D, / et al.: Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. / Clin Infect Dis 2009,48(11):e108-16. CrossRef
28. Rodriguez-Novoa S, Labarga P, D'Avolio A, Barreiro P, Albalate M, Vispo E, Solera C, Siccardi M, Bonora S, Di Perri G, / et al.: Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. / AIDS 2010,24(7):1064-066. CrossRef
29. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K: Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. / Nephrol Dial Transplant 2011,26(10):3224-229. CrossRef
30. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, / et al.: Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT Study. / J Acquir Immune Defic Syndr 2010,55(1):49-7. CrossRef
31. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C, Klein D: Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. / J Acquir Immune Defic Syndr 2010,53(1):62-9. CrossRef
32. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Bonora S, Di Perri G, Back DJ, / et al.: Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. / J Infect Dis 2011,204(1):145-53. CrossRef
33. Jaafar A, Seronie-Vivien S, Malard L, Massip P, Chatelut E, Tack I: Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. / AIDS 2009,23(2):257-59. CrossRef
34. Post FA, Wyatt CM, Mocroft A: Biomarkers of impaired renal function. / Curr Opin HIV AIDS 2010,5(6):524-30. CrossRef
35. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, / et al.: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. / Lancet 2005,365(9466):1231-238. CrossRef
36. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, / et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). / J Hypertens 2007,25(6):1105-187. CrossRef
37. Sola-Del Valle DA, Mohan S, Cheng JT, Paragas NA, Sise ME, D'Agati VD, Barasch J: Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. / Nephrol Dial Transplant 2011,26(7):2387-390. CrossRef
38. Paragas N, Nickolas TL, Wyatt C, Forster CS, Sise M, Morgello S, Jagla B, Buchen C, Stella P, Sanna-Cherchi S, / et al.: Urinary NGAL marks cystic disease in HIV-associated nephropathy. / J Am Soc Nephrol 2009,20(8):1687-692. CrossRef
39. Han TM, Naicker S, Ramdial PK, Assounga AG: A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. / Kidney Int 2006,69(12):2243-250. CrossRef
40. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, Deray AG: Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy. / J Infect Dis 2006,194(11):1481-491. CrossRef
41. Burling KA, Cutillas PR, Church D, Lapsley M, Norden AG: Analysis of molecular forms of urine Retinol-Binding Protein in Fanconi Syndrome and design of an accurate immunoassay. / Clin Chim Acta 2012,413(3-):483-89. CrossRef
42. Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, Wohl D, Shlipak MG: Microalbuminuria in HIV infection. / AIDS 2007,21(8):1003-009. CrossRef
43. Sarafidis PA, Bakris GL: Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. / Nephrol Dial Transplant 2006,21(9):2366-374. CrossRef
44. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CC, Rompalo AM, Schuman P, Klein RS: Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. / J Acquir Immune Defic Syndr 2003,32(2):203-09. CrossRef
45. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG: Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. / Circulation 2010,121(5):651-58. CrossRef
46. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG: Kidney function and the risk of cardiovascular events in HIV-1-infected patients. / AIDS 2010,24(3):387-94. CrossRef
47. Wyatt CM, Hoover DR, Shi Q, Seaberg E, Wei C, Tien PC, Karim R, Lazar J, Young MA, Cohen MH: Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. / J Acquir Immune Defic Syndr 2010,55(1):73-7. CrossRef
48. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/13/85/prepub - 作者单位：Lucy J Campbell (1)
Tracy Dew (2)
Rashim Salota (2)
Emily Cheserem (3)
Lisa Hamzah (1) (3)
Fowzia Ibrahim (1)
Pantelis A Sarafidis (1)
Caje F Moniz (2)
Bruce M Hendry (1)
Mary Poulton (3)
Roy A Sherwood (2)
Frank A Post (1) (3)
1. Academic Department of Renal Sciences, King’s College London, London, United Kingdom
2. Departments of Clinical Biochemistry, King’s College Hospital, London, United Kingdom
3. Sexual Health, King’s College Hospital, London, United Kingdom
文摘
Background Chronic kidney disease is common in HIV positive patients and renal tubular dysfunction has been reported in those receiving combination antiretroviral therapy (cART). Tenofovir (TFV) in particular has been linked to severe renal tubular disease as well as proximal tubular dysfunction. Markedly elevated urinary concentrations of retinal-binding protein (RBP) have been reported in patients with severe renal tubular disease, and low-molecular-weight proteins (LMWP) such as RBP may be useful in clinical practice to assess renal tubular function in patients receiving TFV. We analysed 3 LMWP as well as protein and albumin in the urine of a sample of HIV positive patients. Methods In a cross-sectional fashion, total protein, albumin, RBP, cystatin C, and neutrophil gelatinase-associated lipocalin (NGAL) were quantified in random urine samples of 317 HIV positive outpatients and expressed as the ratio-to-creatinine (RBPCR, CCR and NGALCR). Exposure to cART was categorised as none, cART without TFV, and cART containing TFV and a non-nucleoside reverse-transcriptase-inhibitor (TFV/NNRTI) or TFV and a protease-inhibitor (TFV/PI). Results Proteinuria was present in 10.4- and microalbuminuria in 16.7- of patients. Albumin accounted for approximately 10- of total urinary protein. RBPCR was within the reference range in 95- of patients while NGALCR was elevated in 67- of patients. No overall differences in urine protein, albumin, and LMWP levels were observed among patients stratified by cART exposure, although a greater proportion of patients exposed to TFV/PI had RBPCR >38.8 μg/mmol (343 μg/g) (p--.003). In multivariate analyses, black ethnicity (OR 0.43, 95- CI 0.24, 0.77) and eGFR <75?mL/min/1.73?m2 (OR 3.54, 95- CI 1.61, 7.80) were independently associated with upper quartile (UQ) RBPCR. RBPCR correlated well to CCR (r2--.71), but not to NGALCR, PCR or ACR. Conclusions In HIV positive patients, proteinuria was predominantly of tubular origin and microalbuminuria was common. RBPCR in patients without overt renal tubular disease was generally within the reference range, including those receiving TFV. RBP therefore appears a promising biomarker for monitoring renal tubular function in patients receiving TFV and for distinguishing patients with normal tubular function or mild tubular dysfunction from those with severe renal tubular disease or Fanconi syndrome.